Sirona Biochem Corp. has signed a material transfer agreement with VitamFero, a veterinary healthcare company, to test Sirona's biological preservation technology with the goal of extending the storage time of its live attenuated animal vaccines.
 
Using its chemistry technology, Sirona Biochem develops biological preservation compounds to extend the life of stem cells, blood platelets, islets cells, tissues, organs and other biologics.
 
"By developing technology that can preserve biologics longer, we expand the possibilities for health practitioners to deliver services and solutions in human and animal health," said Neil Belenkie, chief executive officer of Sirona Biochem. "We are pleased to collaborate with VitamFero and believe our synergistic collaboration can result in a benefit for both companies."
 
"Sirona Biochem is developing a unique class of biological preservation compounds that could help improve VitamFero's vaccine storage for a significantly longer period of time and could expand distribution capabilities," said Dr. Pascal Breton, VitamFero¹s chief executive officer. "We are very pleased to be working with the innovative research team at Sirona Biochem."